CRISPR Therapeutics (CRSP) P/S ratio

P/S ratio · fiscal 2024
94.9×

The P/S ratio of CRISPR Therapeutics (CRSP) was 94.9× at the end of fiscal 2024 (December 31, 2024). That is 607.8% higher than the 13.4× of fiscal 2023. Figures as of 18 Nov 2026, 10:53 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio, fiscal 2024
94.9×
Change on fiscal 2023
+607.8%
Highest on record
438.6×fiscal 2018
Lowest on record
6.7×fiscal 2021
Fiscal years on record
62017–2024

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

CRISPR Therapeutics P/S ratio, in more detail

Across the 6 fiscal year-ends on record (2017–2024), the highest was 438.6× in fiscal 2018 and the lowest 6.7× in fiscal 2021.

History · 6 fiscal years

P/S ratio at each fiscal year-end

CRISPR Therapeutics P/S ratio, year by year

CRISPR Therapeutics (CRSP) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
2025——$52.44—
202494.9× 607.8% up$39.36$0.41
202313.4×—$62.60$4.67
2022——$40.65$0.01
20216.7×—$75.78$11.38
2020——$153.11$0.01
201912.0× 97.3% down$60.90$5.09
2018438.6× 1,812.0% up$28.57$0.07
201722.9×—$23.48$1.02
2016——$20.26—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of CRISPR Therapeutics and comparable companies
CompanyP/S ratio
MiniMed Group MMED1.6×
Adaptive Biotechnologies ADPT16.7×
Heartflow HTFL23.5×
Option Care Health OPCH0.8×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on CRSP

CRISPR Therapeutics, figure by figure

CRISPR Therapeutics (CRSP) overview: price, valuation and scorecardAll health care companies by market value

CRISPR Therapeutics P/S ratio: questions and answers

What is CRISPR Therapeutics's P/S ratio?

The P/S ratio of CRISPR Therapeutics (CRSP) was 94.9× at the end of fiscal 2024 (December 31, 2024). That is 607.8% higher than the 13.4× of fiscal 2023.

What are the highest and lowest P/S ratio figures on record for CRISPR Therapeutics?

Across the 6 fiscal year-ends on record (2017–2024), the highest was 438.6× in fiscal 2018 and the lowest 6.7× in fiscal 2021.

How is CRISPR Therapeutics's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For CRISPR Therapeutics it is on record here for 6 fiscal years, 2017 to 2024.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CRISPR Therapeutics (CRSP) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CRSP/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.